

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/632,997 Confirmation No.: 8974
Applicants: Wang *et al.*
Filed: August 1, 2003
TC/A.AU.: 1645
Examiner: Unassigned
Docket No.: 08841.105020 PHA 1070 US
Customer No.: 20786
Title: Compounds with The Bicyclo [4.2.1] Nonane System for the Treatment of
Flaviviridae Infections

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Sir:

The citation of information on the attached Form PTO-1449, "List of Art Cited by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. Copies of all references are enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Applicants do not believe any fees are due because this paper is submitted before the mailing of a first Office action on the merits of the application, as under 37 C.F.R. § 1.97(b)(3). However, the Commissioner is hereby authorized to charge any fees due or credit any overpayment, to Deposit Account No. 11-0980.


Respectfully submitted,


Madeline J. Johnston
Reg. No. 36,174

Date: Jan 30 2004
King & Spalding, LLP
191 Peachtree Street, N.E., Atlanta, GA 30303
Office: (404)572-4600/ Fax: 404-572-5145


CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on January 30, 2004.


Tisha Hardrick

3400089_1

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **1** of **3**

Complete if Known

Application Number	10/632,997
Filing Date	August 1, 2003
First Named Inventor	Peiyuan Wang <i>et al.</i>
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	08841.105020 PHA 1070 US

3399974 1

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/Relevant Figures Appear	T ⁶
		Number	Kind Code (if known)				
	AA	5,026,687		Yarchoan <i>et al.</i>	06-25-1991		
	AB	5,491,135		Blough	02-13-1996		
	AC	5,496,546		Wang <i>et al.</i>	03-05-1996		
	AD	5,633,388		Diana <i>et al.</i>	05-27-1997		
	AE	5,725,859		Omer	03-10-1998		
	AF	5,830,905		Diana <i>et al.</i>	11-03-1998		
	AG	5,837,257		Tsai <i>et al.</i>	11-17-1998		
	AH	5,846,964		Ozeki	12-08-1998		
	AI	5,849,800		Smith	12-15-1998		
	AJ	5,858,389		Elsherbini	01-12-1999		
	AK	5,891,874		Colacino <i>et al.</i>	04-06-1999		
	AL	5,922,757		Chojkier	07-13-1999		
	AM	6,030,960		Morris-Natschke <i>et al.</i>	02-29-2000		
	AN	6,034,134		Gold <i>et al.</i>	03-07-2000		
	AO	6,056,961		Lavie <i>et al.</i>	05-02-2000		
	AP	6,573,248	B2	Ramasamy <i>et al.</i>	06-03-2003		
	AQ	2002/0055483	A1	Watanabe <i>et al.</i>	05-09-2002		
	AR	2002/0147160	A1	Bhat <i>et al.</i>	10-10-2002		
	AS	2003/0008841	A1	Devos <i>et al.</i>	01-09-2003		
	AT	2003/0028013	A1	Wang <i>et al.</i>	02-06-2003		
	AU	2003/0050229	A1	Sommadosi <i>et al.</i>	03-13-2003		
	AV	2003/0060400	A1	LaColla <i>et al.</i>	03-27-2003		
	AW	2003/0083307	A1	Devos <i>et al.</i>	05-01-2003		
	AX	2003/0087873	A1	Stuyver <i>et al.</i>	05-08-2003		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **2** of **3**

Complete if Known

Application Number	10/632,997
Filing Date	August 1, 2003
First Named Inventor	Peiyuan Wang <i>et al.</i>
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	08841.105020 PHA 1070 US

3399974 1

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Office ³	Number	Kind Code ² (if known)				
	BA	FR	2,662,165 ¹	A1 ✓	Univ Pierre et Marie Curie	11-22-1991		
	BB	WO	98/16184	A2 ✓	ICN Pharmaceuticals	04-23-1998		
	BC	WO	99/43691	A1 ✓	Emory University	09-02-1999		
	BD	WO	01/32153	A2 ✓	BioChem Pharma Inc.	05-10-2001		
	BE	WO	01/60315	A2 ✓	BioChem Pharma Inc.	08-23-2001		
	BF	WO	01/68663	A1 ✓	ICN Pharmaceuticals Inc.	09-20-2001		
	BG	WO	01/79246	A2 ✓	Pharmasset, Ltd.	10-25-2001		
	BH	WO	01/90121	A2 ✓	Novirio (Idenix Pharmaceuticals)	11-29-2001		
	BI	WO	01/92282	A2 ✓	Novirio Pharm.; Univ...Cagliari	06-12-2001		
	BJ	WO	02/003997	A1 ✓	ICN Pharmaceuticals Inc.	01-17-2002		
	BK	WO	02/018404	A2 ✓	F. Hoffmann-La Roche AG	03-07-2002		
	BL	WO	02/032920	A2 ✓	Pharmasset Ltd.	04-25-2002		
	BM	WO	02/048165	A2 ✓	Pharmasset, Ltd.	06-20-2002		
	BN	WO	02/057287	A2 ✓	Merck; Isis Pharmaceuticals	07-25-2002		
	BO	WO	02/057425	A2 ✓	Merck; Isis Pharmaceuticals	07-25-2002		
	BP	WO	02/070533	A3	Pharmasset, Ltd.	09-12-2002		
	BQ	WO	02/094289	A1	F. Hoffmann-La Roche AG	11-28-2002		
	BR	WO	02/100415	A2	F. Hoffmann-La Roche AG	12-19-2002		
	BS	WO	03/026589	A2	Idenix; C.N.R.S.; U. Montpellier	04-03-2003		
	BT	WO	03/026675	A1	Novirio (Idenix Pharmaceuticals)	04-03-2003		
	BU	WO	03/051899	A1	Ribapharm Inc.	06-26-2003		
	BV	WO	03/061385	A1	Ribapharm Inc.	07-31-2003		
	BW	WO	03/061576	A2	Ribapharm Inc.	07-31-2003		
	BX	WO	03/062255	A2	Ribapharm Inc.	07-31-2003		
	BY	WO	03/062256	A1	Ribapharm Inc.	07-31-2003		
	BZ	WO	03/062257	A1	Ribapharm Inc.	07-31-2003		


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/632,997
				Filing Date	August 1, 2003
				First Named Inventor	Peiyuan Wang <i>et al.</i>
				Group Art Unit	1645
				Examiner Name	Unassigned
Sheet	3	of	3	Attorney Docket Number	08841.105020 PHA 1070 US

3399974_1

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Office ³	Number	Kind Code ² (if known)				
	CA	WO	03/063771	A2	Pharmasset Ltd.	08-07-2003		
	CB	WO	03/068162	A2	Pharmasset Ltd.	08-21-2003		
	CC	WO	03/072757	A2	Biota Inc.	09-04-2003		
	CD	WO	03/093290	A2	Genelabs Technologies	11-13-2003		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
	CE	ANDERSON, G. L., <i>et al.</i> , "Pyridopyrimidines. 7. Ribonucleosides structurally related to the antitumor antibiotic sangivamycin," <i>J. Org. Chem.</i> , 42(6):997-1000 (1977).		
	CF	CARROLL, Steven S. et al. "Inhibition of Hepatitis C Virus RNA Replication by 2'-Modified Nucleoside Analogs" <i>The Journal of Biological Chemistry</i> , 278(14):11979-11984 (2003).		
	CG	DYMOCK, B.W., <i>et al.</i> , "Novel approaches to the treatment of hepatitis C virus infection," <i>Antiviral Chemistry & Chemotherapy</i> , 11(2):79-96 (2000).		
	CH	HARRY-O'KURU, Rogers E. et al. "2'-C-Alkylribonucleosides: Design, Synthesis, and Conformation" <i>Nucleosides & Nucleotides</i> , 16(7-9):1457-1460 (1997).		
	CI	PFLEIDERER, W., <i>et al.</i> , "Allgemeine Synthese von Pteridin-N-8-glycosiden," <i>Chem. Ber.</i> , 106, 317-331 (1973).		
	CJ	RIZKALLA, B.H., <i>et al.</i> , "Pyrido[2,3-d]pyrimidines. III. Synthesis of some 8-(β-D-ribofuranosyl)pyrido[2,3-d]pyrimidines structurally related to the antibiotic sangivamycin," <i>J. Org. Chem.</i> , 37(25):3980-3985 (1972).		

3399974_1

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.